EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Efficacy of Anti-Amyloid Monoclonal Antibody Immunotherapy on Cognitive Progression in Alzheimer's Disease Patients : A Systematic Review of Randomized Controlled Trials and Primary Studies

Luh Wayan Puspa Ningsih, Ida Bagus Kade Satyagraha

The Indonesian Journal of General Medicine · 08.07.2026 · 42 (1) · 341-375

DOI: 10.70070/sdjae253 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Indonesian Journal of General Medicine, online erschienen am 08.07.2026. Verfasst von Luh Wayan Puspa Ningsih und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Alzheimer's disease (AD) is the leading cause of dementia worldwide, with the amyloid cascade hypothesis implicating amyloid-beta (Aβ) accumulation as a primary pathogenic driver. Anti-amyloid monoclonal antibodies (mAbs) represent the most advanced class of disease-modifying therapies, yet their cognitive efficacy, safety profile, and clinical meaningfulness remain subjects of ongoing debate. This systematic review synthesizes evidence from randomized controlled trials (RCTs) evaluating anti-amyloid mAb immunotherapy across all agents and disease stages.

Methods

A systematic review was conducted following PRISMA 2020 guidelines. Eligible studies comprised Phase II and III placebo-controlled RCTs evaluating anti-amyloid mAbs in patients with mild cognitive impairment or mild-to-moderate AD. Primary outcome was change in Clinical Dementia Rating-Sum of Boxes (CDR-SB). Risk of bias was assessed using Cochrane RoB 2.0.

Results

Twenty publications representing 15 distinct trials (N>36,000 participants) evaluating seven mAbs were included. Second-generation mAbs (lecanemab, donanemab) demonstrated statistically significant CDR-SB slowing (lecanemab: Δ–0.45, 95% CI –0.67 to –0.23, p

Zitieren

APA

Ningsih, L. W. P., & Satyagraha, I. B. K. (2026). Efficacy of Anti-Amyloid Monoclonal Antibody Immunotherapy on Cognitive Progression in Alzheimer's Disease Patients : A Systematic Review of Randomized Controlled Trials and Primary Studies. The Indonesian Journal of General Medicine, 42(1), 341-375. https://doi.org/10.70070/sdjae253

Vancouver

Ningsih LWP, Satyagraha IBK. Efficacy of Anti-Amyloid Monoclonal Antibody Immunotherapy on Cognitive Progression in Alzheimer's Disease Patients : A Systematic Review of Randomized Controlled Trials and Primary Studies. The Indonesian Journal of General Medicine. 2026;42(1):341-375. doi:10.70070/sdjae253

BibTeX
@article{Ningsih2026,
  author = {Ningsih, Luh Wayan Puspa and Satyagraha, Ida Bagus Kade},
  title = {Efficacy of Anti-Amyloid Monoclonal Antibody Immunotherapy on Cognitive Progression in Alzheimer's Disease Patients : A Systematic Review of Randomized Controlled Trials and Primary Studies},
  journal = {The Indonesian Journal of General Medicine},
  year = {2026},
  volume = {42},
  number = {1},
  pages = {341--375},
  doi = {10.70070/sdjae253}
}
Kostenlos starten →